| Identification | Back Directory | [Name]
(S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide | [CAS]
1174130-61-0 | [Synonyms]
CS-2732
LY2456302
Aticaprant
Aticaprant (CERC-501)
CERC-501(LY-2456302,Aticaprant)
LY2456302;LY 2456302;CERC501;CERC 501
(S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide
4-[4-[[(2S)-2-(3,5-Dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluorobenzamide
Benzamide, 4-[4-[[(2S)-2-(3,5-dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluoro- | [Molecular Formula]
C26H27FN2O2 | [MDL Number]
MFCD22572355 | [MOL File]
1174130-61-0.mol | [Molecular Weight]
418.5 |
| Chemical Properties | Back Directory | [Boiling point ]
519.2±50.0 °C(Predicted) | [density ]
1.201±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 1 mg/ml; DMSO: 5 mg/ml; Ethanol: 3 mg/ml; PBS (pH 7.2): insol | [form ]
A solid | [pka]
15.61±0.50(Predicted) | [color ]
White to off-white | [InChIKey]
ZHPMYDSXGRRERG-DEOSSOPVSA-N | [SMILES]
C(N)(=O)C1=CC=C(OC2=CC=C(CN3CCC[C@H]3C3=CC(C)=CC(C)=C3)C=C2)C(F)=C1 |
| Hazard Information | Back Directory | [Uses]
Aticaprant is a κ-?opioid receptor agonist which may be used in the treatment of neurological diseases and disorders such as Alzheimer''s disease. | [in vivo]
Aticaprant (CERC-501) has a rapid absorption (tmax=1-2 h) and good oral bioavailability (F=25%). Oral Aticaprant (CERC-501) administration selectively and potently occupies central kappa opioid receptors (ED50=0.33 mg/kg), without evidence of mu or delta receptor occupancy. LY2456302 potently blocks kappa-agonist-mediated analgesia and disruption of prepulse inhibition, without affecting mu-agonist-mediated effects at doses >30-fold higher. Aticaprant (CERC-501) produces antidepressant-like effects in the mouse forced swim test and enhances the effects of imipramine and citalopram. Aticaprant (CERC-501) reduces ethanol self-administration in alcohol-preferring rats[1]. Aticaprant (CERC-501) alleviates the nicotine withdrawal syndrome, as evidenced by decreased expression of nicotine withdrawal induced anxiety-related behavior, somatic signs, and CPA, and increased hotplate latency in nicotine withdrawn mice following pre-treatment[2]. | [storage]
Store at -20°C |
|
| Company Name: |
ExSyn Corp
|
| Tel: |
+91-2240546474 |
| Website: |
www.exsyncorp.com |
|